Table 4 Analysis of demographic, clinical, histological, molecular and therapeutic characteristics of patients treated with mastectomy and breast conservative therapy (BCT) (test Pearson Khi2)
From: Concurrent chemoradiotherapy in adjuvant treatment of breast cancer
Patients characteristics | Mastectomy [n = 205] No (%) | BCT [n = 39] No (%) | p value |
|---|---|---|---|
Age | |||
   <40 | 48 (23.4%) | 6 (15.4%) | 0.268 |
   ≥40 | 157 (76.6%) | 33 (84.6%) |  |
Menopausal status | |||
   No | 129 (67.5%) | 23 (63.9%) | 0.669 |
   Yes | 62 (32.5%) | 13 (36.1%) |  |
Side | |||
   Right | 48 (43.6%) | 71 (53%) | 0.146 |
   Left | 62 (56.4%) | 63 (47%) |  |
Histology | |||
   DIC | 183 (91.1%) | 36 (100%) | 0.062 |
   LIC | 18 (9%) | 0 |  |
SBR | |||
   I | 13 (6.6%) | 4 (10.5%) | 0.53 |
   II | 130 (65.7%) | 26 (68.4%) |  |
   III | 55 (27.8%) | 8 (21.1%) |  |
Hormone receptors | |||
ER | |||
   Positive | 120 (60.3%) | 28 (71.8%) | 0.877 |
   Negative | 79 (39.7%) | 11 (28.2%) |  |
PR | |||
   Positive | 61 (57.5%) | 23 (59%) | 0.877 |
   Negative | 45 (42.5%) | 16 (41%) |  |
Tumour | |||
   pT1 | 25 (12.4%) | 10 (25.6%) | 0.003 |
   pT2 | 111 (55.2%) | 27 (69.2%) |  |
   pT3 | 55 (27.4%) | 2 (5.1%) |  |
   pT4 | 10 (5%) | 0 |  |
pN, axillary | |||
   pN0 | 49 (23.9%) | 11 (28.2%) | 0.285 |
   pN1 | 57 (27.8%) | 15 (38.5%) |  |
   pN2 | 63 (30.7%) | 10 (25.6%) |  |
   pN3 | 36 (17.6%) | 3 (7.7%) |  |
Protocol | |||
   Anthracycline | 89 (43.4%) | 21 (53.8%) | 0.23 |
   CMF | 116 (56.6%) | 18 (46.2%) |  |
Breast/thoracic wall irradiation | |||
   Yes | 194 (94.6%) | 39 (100%) | 0.139 |
   No | 11 (5.4%) | 0 |  |
Prophylactic supraclavicular fossa radiotherapy | |||
   Yes | 193 (94.1%) | 38 (97.4%) | 0.402 |
   No | 12 (5.9%) | 1 (2.6%) |  |
Internal mammary radiotherapy | |||
   Yes | 195 (94.1%) | 38 (97.4%) | 0.523 |
   No | 10 (5.9%) | 1 (2.6%) |  |
Axillary radiotherapy | |||
   Yes | 42 (20.5%) | 7 (17.9%) | 0.717 |
   No | 163 (79.5%) | 32 (82.1%) |  |